High profile fundie warns these 10 ASX shares have “bubble” valuations, page-3

It is surprising that a "high profile fundie" is so ignorant of the usual evolutionary path of a biotech, requiring many years of expensive trials and little balancing income. And only a minority of those have successful P3 trials and FDA imprimatur.
ALL developing biotechs are valuation bubbles, with prices based on hope. The fundie told us nothing about MSB.
MBS is a minute before a bright dawn on this evolutionary trail. The fundie is confusing price with value. He is bewitched by the market's siren song and can't hear Silviu's sweet notes. The job is almost done.